Element Biosciences’ bid to claim a slice of a DNA sequencing technology ... instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology, like its ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

China has banned the import of Illumina’s next-generation sequencing ... and use a technology known as sequencing by synthesis (SBS) to enhance DNA short-read sequence generation.

GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Illumina, Inc.

Illumina, Inc., a global leader in next-generation sequencing and array-based technologies ... It focus on innovation has established us as a global leader in DNA sequencing and array-based ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

Today, next-generation sequencing solutions from Roche play an important role in the sequencing ecosystem. Our KAPA sample preparation products offer high-performance DNA, RNA library prep and target ...